Decision-making for Subsequent Therapy for Patients With Recurrent or Advanced Endometrial Cancer Based on the Platinum-free Interval.
Masafumi YasunagaHideaki YahataKaoru OkugawaEmiko HoriKazuhisa HachisugaShoji MaenoharaKeisuke KodamaHiroshi YagiTatsuhiro OhgamiIchiro OnoyamaKazuo AsanomaKiyoko KatoPublished in: American journal of clinical oncology (2023)
Pembrolizumab plus lenvatinib seems to be a better treatment choice for patients with REC or AEC with a PFI of <6 months. For a PFI of ≥6 months, pembrolizumab plus lenvatinib or PCC can be used depending on the degree of residual side -effects associated with cytotoxic agents.